Medication info
Tradiam Duo Tablet 2.5/1000 mg

Tradiam Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
Light pink, double convex, oval film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP × 5 packs)]
Approval status
Active

MFDS item code 201802273 · Approved 2018.05.31 · Insurance code 643705510

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse effects associated with metformin use, dose increases should be made gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Contraindications).

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is a combination therapy of linagliptin and metformin, which helps type 2 diabetes patients control their blood sugar levels along with diet and exercise therapy. It effectively improves blood glucose levels and supports healthy blood sugar management.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse effects associated with metformin use, dose increases should be made gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Contraindications).

Precautions

This medicine helps to control blood sugar levels. However, it should not be administered to patients with specific diseases or conditions. For example, this medicine may pose risks to patients who are allergic to its components, patients with type 1 diabetes, patients with severe renal impairment, or those with acute infections or serious trauma. Additionally, this drug can cause a serious side effect called lactic acidosis, so caution is especially needed in patients with reduced kidney function or compromised heart or liver function. During treatment with this drug, hypoglycemia may occur. Therefore, when used with other hypoglycemic agents or insulin, blood sugar levels should be monitored frequently and doses adjusted as necessary. Renal function should be regularly checked to ensure the drug does not burden the body, and in certain situations such as surgery or radiological examinations, the medication may need to be temporarily discontinued. This drug is not recommended for pregnant or breastfeeding women and should generally not be used in children or pediatric patients under 10 years of age. If abdominal pain, persistent vomiting, severe muscle pain, shortness of breath, skin rash, vesicular symptoms appear, immediate consultation with a physician should be sought. Additionally, this drug may lower vitamin B12 levels, so regular blood tests are needed during prolonged use. This drug may interact with other medications, so if you are taking any other drugs, be sure to inform your physician or pharmacist. Lastly, keep this medicine out of reach of children and store it away from moisture and direct sunlight.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced and deficient vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
Show 156 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • epigastric pain
  • ileocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • pneumoconiosis
  • laceration
  • palpitations
  • dry eye syndrome
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid enlargement
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory loss
  • chest discomfort
  • myasthenia
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • epigastric pain
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood creatinine
  • facial swelling
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • headache
  • subdural effusion
  • voice disorder
  • dyspnea
  • epistaxis
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help preserve the drug's effectiveness and safety for a long time.

Appearance and packaging

Appearance

Light pink, double convex, oval film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP × 5 packs)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.